Clinical trials: Obese Subjects
Hypothalamic Obesity
Study of Tesomet With Open-label Extension in Subjects With Hypothalamic Obesity (HO)
This study will evaluate the safety and efficacy of Tesomet (tesofensine + metoprolol) in subjects 18 years of age or older, with HO
- Trial name
- NCT05147415
- Testing
- Tesomet
- Where
- United States
- Sponsor
- Saniona
Metabolic Syndrome X
Evaluation of the Effects of a L.Reuteri Strain on Markers of Inflammation, Cardiovascular Risk and Fatty Liver Disease
The purpose of this study is the evaluation of the effects in obese patients with metabolic syndrome on the composition of the intestinal microbiota, markers of the syndrome (hypertension, dyslipidemia, inflammation biomarkers…
- Trial name
- PROSIR (NCT02972567)
- Testing
- Lactobacillus spp, Control
- Where
- Spain
- Volunteers
- 60 people
- Sponsor
- Biosearch S.A.
Obese Subjects With Polycystic Ovary Syndrome (PCOS)
A Multicenter, Randomized, Double-blind, Placebo-parallel-controlled Phase II Clinical Study Evaluating the Efficacy and Safety of HRS9531 Injection in Obese Subjects With Polycystic Ovary Syndrome
Randomized, double-blind, placebo-controlled study of HRS9531 in PCOS subjects
- Trial name
- NCT06595797
- Testing
- HRS9531
- Volunteers
- 144 people
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Obesity
A Study of ABBV-295 Subcutaneous Injections to Assess Adverse Events and Pharmacokinetics in Adult Participants With Obesity
This study is to assess adverse events, change in body weight and pharmacokinetics in adult participants with obesity receiving ABBV-295 subcutaneous injections or matching placebo.
- Trial name
- NCT07291232
- Testing
- ABBV-295
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- AbbVie
Overweight
A Single Dose Study Of PF-04620110 In Overweight And Obese, Otherwise Healthy Volunteers
PF-04620110 is a novel compound proposed for the treatment of Type 2 diabetes mellitus. The purpose of this study is to characterize the safety, tolerability, pharmacokinetics and pharmacodynamics following a single oral dose.
- Trial name
- NCT00799006
- Testing
- PF-04620110
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Pfizer
Obesity
A Study Comparing the Efficacy and Safety of HRS9531 Injection With Semaglutide Injection in Subjects With Obesity
This study is a multicenter, randomized, open-label, parallel-controlled, phase III study to compare the efficacy, safety, and tolerability of HRS9531 versus semaglutide once weekly (QW) in adult subjects with obesity
- Trial name
- NCT07285902
- Testing
- HRS9531 injection, Semaglutide Injection
- Where
- 2 sites in China
- Volunteers
- 572 people
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Healthy
Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin (JNJ-28431754) in Otherwise Healthy Obese Volunteers
The purpose of this study is to assess the pharmacokinetics (ie, how the body affects the drug) and pharmacodynamics (ie, how the drug affects the body) of increasing doses of canagliflozin (JNJ-28431754) in healthy obese…
- Trial name
- NCT01756404
- Testing
- Canagliflozin (JNJ-28431754)
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Healthy, Non-diabetic Overweight or Obese
A Study of BGM0504 Tablets in Healthy and Non-diabetic Overweight or Obese Chinese Subjects
A Randomized, Double-Blind, Placebo-Controlled, Single/Multiple-dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BGM0504 Tablets Orally Administered in Healthy and Non-diabetic Overweight or Obese…
- Trial name
- NCT07239973
- Testing
- BGM0504 tablets
- Where
- China
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- BrightGene Bio-Medical Technology Co., Ltd.
Type 2 Diabetes Mellitus
Study of MEDI0382 in Combination With Dapagliflozin and Metformin in Overweight/Obese Participants With Type 2 Diabetes
A Phase 2 study Comparing the effects on glucose control of MEDI0382 in combination with Dapagliflozin and Metformin compared to placebo in combination with Dapagliflozin and Metformin in overweight/obese participants with Type 2…
- Trial name
- NCT03444584
- Testing
- MEDI0382, Dapaglifozin, Metformin
- Where
- 8 sites in Germany, Hungary and 1 more
- Volunteers
- 49 people
- Sponsor
- MedImmune LLC
Insulin Resistance
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of (PEG)-BHD1028
Adiponectin has been known to play critical roles in various physio-regulatory processes, and adiponectin deficiency may contribute to insulin resistance. (PEG)-BHD1028 was developed as an agonist of adiponectin receptors.
- Trial name
- NCT06563115
- Testing
- (PEG)-BHD1028 Single Ascending Dose, (PEG)-BHD1028 Multiple Ascending Dose
- Where
- United States
- Volunteers
- 64 people
- Sponsor
- EncuraGen, Inc
Health Adult Subjects, Obesity & Overweight
A Study to Evaluate Safety, Tolerability and Pharmacokinetics of Orally Administered TIX100 in Healthy Subjects
Randomized, Placebo-controlled Study to determine the safety and tolerability of multiple oral doses of TIX100 administered daily for 28 days to otherwise healthy overweight/obese subjects.
- Trial name
- NCT07675590
- Testing
- TIX100
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- TIXiMED, Inc.
Type 2 Diabetes Mellitus
A Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of MK-5823 in Overweight or Obese Participants Who Are Healthy or Have Type 2 Diabetes Mellitus (MK-5823-002)
The purpose of this study is to assess the multiple rising dose safety/tolerability and pharmacokinetics of MK-5823 in overweight/obese participants who are healthy and overweight/obese participants with Type 2 diabetes mellitus…
- Trial name
- NCT01614782
- Testing
- MK-5823
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes
Safety and Tolerability Study of Cotadutide in Japanese Obese Subjects With Type 2 Diabetes Melitus
This is a Phase 1 study designed to assess the safety and tolerability of MEDI0382 (Cotadutide) in Japanese T2DM patients.
- Trial name
- NCT04208620
- Testing
- Cotadutide
- Where
- 3 sites in Japan
- Volunteers
- 16 people
- Sponsor
- AstraZeneca
Thrombosis
Study Investigation Pharmacokinetics and Pharmacodynamics of CS1
SAD study: Eighteen subjects will be included in the SAD study (single dose) in 3 parallel arms, each with 6 subjects. The 3 arms will receive a single dose of one of the CS1 formulations I, II or III.
- Trial name
- NCT03903302
- Testing
- CS1-Sodium Valproate
- Where
- Sweden
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Cereno Scientific AB
Obesity, Morbid Obesity
Effects of RM-493 on Energy Expenditure in Obese Individuals
Background: RM-493 is a drug that stimulates parts of the brain that control eating and metabolism. It has helped to reduce body weight and improve insulin sensitivity in lab tests.
- Trial name
- NCT01867437
- Testing
- RM-493
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Rhythm Pharmaceuticals, Inc.
Obesity
A Single Dose Pharmacokinetic Study of Lorcaserin Hydrochloride in Obese Pediatric Subjects 6 to 11 Years of Age
Study will evaluate the pharmacokinetics (PK), safety and tolerability of a single 10 mg dose of lorcaserin hydrochloride in obese pediatric subjects 6 to 11 years of age.
- Trial name
- NCT02398669
- Testing
- Lorcaserin hydrochloride
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Eisai Inc.
Insulin Resistance, Obesity
Tea-beetroot-venous Occlusion Plethysmography
In the present study, muscle perfusion will be studied before and after an oral glucose challenge following a fasting period.
- Trial name
- NCT01746329
- Testing
- Tea, Beet root
- Where
- Netherlands
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Unilever R&D
NAFLD
A Study of Multiple Doses of HM15211(Efocipegtrutide) in Obese Subjects With NAFLD
This study is a phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple doses of HM15211 in obese subjects with NAFLD
- Trial name
- NCT03744182
- Testing
- HM15211
- Where
- United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- Hanmi Pharmaceutical Company Limited
Diabetes, Metabolism and Nutrition Disorder
Trial Investigating the Effect of Semaglutide on Energy Intake, Appetite Sensations, Postprandial Glucose and Triglyceride Metabolism and Gastric Emptying in Obese Subjects Compared With Placebo
This trial is conducted in Europe. The aim of the trial is to investigate the effect of semaglutide on energy intake, appetite sensations, postprandial glucose and triglyceride metabolism and gastric emptying in obese subjects…
- Conditions
- Diabetes, Metabolism and Nutrition Disorder, Obesity
- Trial name
- NCT02079870
- Testing
- semaglutide
- Where
- United Kingdom
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Overweight and Obesity
A Study Evulating DA-302168S Tablets in Overweight/Obese Subjects
The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of continuous oral administration of DA-302168S tablets for 28 days in overweight/obese subjects.
- Trial name
- DA168 (NCT06541730)
- Testing
- DA-302168S
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Chendu DIAO Pharmaceutical Group CO., LTD.